All updates
All updates
today 49顶刊论文（社媒热度）评分4444 顶刊论文（社媒热度）精选评分7171 Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
FDA Drugs评分2828 Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels
NEJM评分3030 PML Resolution after Treatment with Virus-Specific T Cells Followed by HCT
NEJM评分2222 Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia
NEJM评分2525 Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
NEJM评分3939 Giredestrant plus Everolimus in Advanced Breast Cancer
The Lancet Oncology精选评分7474 [News] 2026 ASTRO Annual Meeting
Nature Medicine精选评分6161 Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial
BioPharma Dive评分3333 3 takeaways from a European obesity scientific meeting
BioSpace精选评分6161 Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
BioSpace精选评分6262 Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
BioSpace精选评分5555 BMS reports liver injury events in lung disease program, with key readout near
Endpoints News评分4141 #EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy
STAT News评分3232 STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy
STAT News评分4242 STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
中文产业新闻Chinese source评分3838 emugrobart肥胖适应症II期开发终止，Chugai拟重启SMA开发
中文产业新闻Chinese source评分3636 Nature Medicine发表CD19 CAR-T治疗难治性ACPA阳性类风湿关节炎I期临床研究
中文产业新闻Chinese source评分5656 uniQure亨廷顿病基因疗法AMT-130 I/II期主要终点未达统计学显著 股价跌37%
中文产业新闻精选Chinese source评分6161 武田泽索昔替尼头对头3期试验优于氘可来昔替尼，斑块状银屑病PASI 100完全清除率超2.5倍
中文产业新闻Chinese source评分4848 Kodiak Sciences DAYBREAK III期与Eylea疗效持平，股价单日暴涨178%
中文产业新闻Chinese source评分4545 替尔泊肽+Eloralintide 1b期联合用药31周减重29%刷新纪录（PPT）
中文产业新闻Chinese source评分5959 礼来公布 retatrutide 三靶点 GLP-1 的 TRIUMPH-2 试验详细结果
中文产业新闻Chinese source评分3939 砍掉一条管线，启动三项III期！罗氏减重管线大洗牌
中文产业新闻Chinese source评分5050 默沙东Tulisokibart在中重度化脓性汗腺炎2b期达到主要及关键次要终点
文献与产业新闻精选评分5858 Four-year data raise durability questions for uniQure’s Huntington gene therapy
顶刊论文（社媒热度）精选评分5959 Permissive Blood Pressure Targets in Pediatric Critical Care: The PRESSURE Randomized Clinical Trial.
顶刊论文（社媒热度）精选评分8282 Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
顶刊论文（社媒热度）精选评分6464 Giredestrant plus Everolimus in Advanced Breast Cancer.
顶刊论文（社媒热度）精选评分7373 Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
顶刊论文（社媒热度）精选评分6060 Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.
Endpoints News评分4242 #EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity
medRxiv Oncology精选评分4646 Axitinib in Progressive Metastatic Pheochromocytoma and Paraganglioma: Results of a Phase II Study
中文产业新闻精选Chinese source评分4848 uniQure 亨廷顿病基因疗法 AMT-130 四年随访数据疗效大幅降低
中文产业新闻Chinese source评分3636 罗氏终止抗肌肉抑制素抗体 emugrobart 开发
Endpoints News评分3131 Patient death raises liver questions ahead of Bristol Myers readout
The Lancet精选评分6262 [Articles] 8 weeks versus 12 weeks of sofosbuvir–velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India
The Lancet精选评分5555 [Articles] Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
监管与产业动态评分4343 Experimental drug may reduce lymphedema swelling and scarring
监管与产业动态评分22 phase 2 - Fierce Biotech